Header cover image

Swiss Biotech Stocks

Results

14

0 new

Even though biotechnology stocks can be very risky, they can also offer some of the biggest rewards with huge profits on offer when you find the right one. The companies below all have reasonable balance sheets and value, giving the best chance of finding a gem.

14 companies

Roche Holding

Market Cap: CHF 206.6b

Engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.

ROG

CHF 257.70

7D

-1.2%

1Y

5.4%

Novartis

Market Cap: CHF 191.4b

Engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally.

NOVN

CHF 97.71

7D

-0.2%

1Y

0.6%

Galderma Group

Market Cap: CHF 29.6b

Operates as a dermatology company worldwide.

GALD

CHF 124.50

7D

7.8%

1Y

70.5%

Sandoz Group

Market Cap: CHF 19.0b

Develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide.

SDZ

CHF 44.04

7D

2.6%

1Y

29.9%

Siegfried Holding

Market Cap: CHF 3.9b

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.

SFZN

CHF 90.00

7D

0.2%

1Y

-8.5%

Tecan Group

Market Cap: CHF 2.1b

Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.

TECN

CHF 161.10

7D

-0.06%

1Y

-47.7%

SKAN Group

Market Cap: CHF 1.6b

Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.

SKAN

CHF 69.80

7D

-2.6%

1Y

-12.3%

Cosmo Pharmaceuticals

Market Cap: CHF 992.9m

Focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

COPN

CHF 62.00

7D

5.6%

1Y

-12.9%

PolyPeptide Group

Market Cap: CHF 686.3m

Operates as a contract development and manufacturing company in Europe, the United States, and India.

PPGN

CHF 20.80

7D

1.2%

1Y

-30.4%

Basilea Pharmaceutica

Market Cap: CHF 581.5m

Engages in the discovering, developing, and commercializing drugs for bacterial or fungal infections.

BSLN

CHF 47.40

7D

0.9%

1Y

20.5%

Santhera Pharmaceuticals Holding

Market Cap: CHF 153.9m

A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.

SANN

CHF 11.96

7D

1.0%

1Y

42.9%

Newron Pharmaceuticals

Market Cap: CHF 137.7m

A biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States.

NWRN

CHF 6.90

7D

2.4%

1Y

-13.5%

Xlife Sciences

Market Cap: CHF 113.1m

Focuses on the development and commercialization of research projects in the life sciences sector.

XLS

CHF 19.70

7D

-0.8%

1Y

-33.4%

Relief Therapeutics Holding

Market Cap: CHF 27.6m

A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally.

RLF

CHF 2.20

7D

3.3%

1Y

85.2%